FDA approves Voquezna for erosive esophagitis, gastroesophageal reflux diseaseFDA approves Voquezna for erosive esophagitis, gastroesophageal reflux disease
In a significant milestone, the U.S. Food and Drug Administration (FDA) has greenlit Phathom Pharmaceuticals’ revolutionary therapy, Voquezna (vonoprazan), heralding a new era in the treatment landscape for erosive esophagitis